Crinetics Gains on Vertex Deal, Solstice Acquire Element, Terawulf Jumps
Today's biggest winners and losers in the stock market, a look at the notable movers: On this episode of Stock Movers:- Vertex Pharmaceuticals (VRTX) agreed to buy Crinetics Pharmaceuticals (CRNX) for $10 billion in cash to expand into endocrinology, including medicines for acromegaly and hormone disorders. The purchase price of $85 per share is a 102% premium over where Crinetics shares closed on Monday. The deal, which has been approved by both boards, is expected to close in the third quarter.- Honeywell International spinoff Solstice Advanced Materials (SOLS) will acquire Element…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.